Skip to main content
Equibles

RHUMBLINE ADVISERS

Position in ENTA — Enanta Pharmaceuticals Inc

CIK 1115418 BOSTON, MA
Back to ENTA Full portfolio

Position in ENTA

as of Jun 30, 2026 · filed Aug 12, 2026
Position Value
$504,045
+$107,426 QoQ
Shares Held
34,571
+10.1% QoQ
Ownership
0.119%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#50
of 122 holders
Holding Since
Mar 2020
26 quarters on record
Voting authority Sole 21% Shared 0% None 79%

Common Shares in ENTA Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

RHUMBLINE ADVISERS holds $1,414,750,230 across 329 Biotechnology names. ENTA ranks #182 (0.0% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 VRTX
Vertex Pharmaceuticals Inc / Ma
 396,380 $196,893,837
2 REGN
Regeneron Pharmaceuticals, Inc.
 157,794 $98,390,870
3 MRNA
Moderna, Inc.
 809,853 $56,714,005
4 ALNY
Alnylam Pharmaceuticals, Inc.
 165,579 $49,844,246
5 INCY
Incyte Corp
 428,533 $48,578,500
6 RVMD
Revolution Medicines, Inc.
 226,008 $42,326,778
7 ROIV
Roivant Sciences Ltd.
 1,178,789 $41,717,342
8 JAZZ
Jazz Pharmaceuticals plc
 163,018 $39,282,447

All Filings in ENTA

Export CSV
26 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $504,045 34,571
2026-03-31 $396,619 31,403
2025-12-31 $454,948 28,849
2025-09-30 $369,980 30,909
2025-06-30 $244,248 32,308
2025-03-31 $171,892 31,140
2024-12-31 $213,273 37,091
2024-09-30 $374,669 36,165
2024-06-30 $448,321 34,566
2024-03-31 $576,494 33,018
2023-12-31 $304,074 32,314
2023-09-30 $362,801 32,480
2023-06-30 $1,385,521 64,744
2023-03-31 $2,582,579 63,862
2022-12-31 $2,794,130 60,063
2022-09-30 $3,112,355 60,003
2022-06-30 $2,636,720 55,780
2022-03-31 $3,824,145 53,725
2021-12-31 $4,048,290 54,136
2021-09-30 $3,133,639 55,160
2021-06-30 $2,726,683 61,956
2021-03-31 $3,256,057 66,019
2020-12-31 $2,747,319 65,257
2020-09-30 $2,726,611 59,559
2020-06-30 $3,095,095 61,643
2020-03-31 $2,979,288 57,929